OR WAIT 15 SECS
The Belgian biopharmaceutical company has formed a subsidiary in the United States, and appointed Daniel Schneider as its general manager.
On Oct. 16, 2017, Ablynx, a Belgian biopharmaceutical company focused on the discovery and development of nanobodies, announced the establishment of its US-based subsidiary, Ablynx, Inc., and the appointment of Daniel Schneider as general manager to lead the commercialization of caplacizumab in North America.
Caplacizumab is the company’s bivalent anti-von Willebrand factor nanobody, a proprietary therapeutic protein based on single-domain antibody fragments, and is being developed for treating acquired thrombotic thrombocytopenic purpura, a rare, life-threatening, autoimmune blood clotting disorder.
Schneider, who will operate out of the United States in an East Coast-based office, has 25 years of experience in establishing and leading commercial operations for a number of companies in the life sciences industry. Most recently, Schneider was the general manager of the specialty pharmaceuticals business unit at BTG International.
"The establishment of Ablynx, Inc. is an important milestone for the company and confirms our commitment to becoming a fully integrated international biopharmaceutical company. We are very pleased that Dan is joining us. He brings many years of experience in setting up commercial organizations and leading multiple successful product launches in the [US],” said Dr. Edwin Moses, CEO of Ablynx, in a company press release. “We look forward to joining forces to further develop our commercial infrastructure in preparation of the potential launch of caplacizumab."